Fig. 1From: The CANVAS Program: implications of canagliflozin on reducing cardiovascular risk in patients with type 2 diabetes mellitus(Modified with permission from De Fronzo et al. [21])Renal actions of SGLT2 inhibitors. SGLT2, sodium glucose co-transporter 2; SGLT1, sodium glucose co-transporter 1Back to article page